Effect of intensive lifestyle intervention on bodyweight and glycaemia in early type 2 diabetes (DIADEM-I): an open-label, parallel-group, randomised controlled trial

Type 2 DiabetesGlycemic Control

Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials

Lancet Diabetes Endocrinol.

Zoungas S, Arima H, Gerstein HC, Holman RR, Woodward M, Reaven P, Hayward RA, Craven T, Coleman RL, Chalmers J; Collaborators on Trials of Lowering Glucose (CONTROL) group

doi: 10.1016/S2213-8587(17)

COMMENTED

Type 2 Diabetes

Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial

Lancet Diabetes Endocrinol.

Lean MEJ, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, Peters C, Zhyzhneuskaya S, Al-Mrabeh A, Hollingsworth KG, Rodrigues AM, Rehackova L, Adamson AJ, Sniehotta FF, Mathers JC, Ross HM, McIlvenna Y, Welsh P, Kean S, Ford I, McConnachie A, Messow CM, Sattar N, Taylor R

doi: 10.1016/S2213-8587(19)30068-3.

Diabetes - GeneralType 2 DiabetesGlycemic Control

Efficacy of the Telemedical Lifestyle intervention Program TeLiPro in Advanced Stages of Type 2 Diabetes: A Randomized Controlled Trial

Diabetes Care.

Kempf K, Altpeter B, Berger J, Reuß O, Fuchs M, Schneider M, Gärtner B, Niedermeier K, Martin S

doi: 10.2337/dc17-0303.

COMMENTED

Type 2 Diabetes

Use of professional-mode flash glucose monitoring, at 3-month intervals, in adults with type 2 diabetes in general practice (GP-OSMOTIC): a pragmatic, open-label, 12-month, randomised controlled trial

★ 1 Recommended and commented by Prof. emer. Dr Ulrich Keller, Faculty Member

Lancet Diabetes Endocrinol.

Furler J, O'Neal D, Speight J, Blackberry I, Manski-Nankervis JA, Thuraisingam S, de La Rue K, Ginnivan L, Doyle R, Holmes-Truscott E, Khunti K, Dalziel K, Chiang J, Audehm R, Kennedy M, Clark M, Jenkins A, Lake AJ, Januszewski AS, Catchpool M, Liew D, Clarke P, Best J

doi: 10.1016/S2213-8587(19)30385-7.

COMMENTED

Type 1 DiabetesGlycemic Control

Efficacy and safety of suspend-before-low insulin pump technology in hypoglycaemia-prone adults with type 1 diabetes (SMILE): an open-label randomised controlled trial

Lancet Diabetes Endocrinol.

Bosi E, Choudhary P, de Valk HW, Lablanche S, Castañeda J, de Portu S, Da Silva J, Ré R, Vorrink-de Groot L, Shin J, Kaufman FR, Cohen O, SMILE Study Group.

doi: 10.1016/

Type 2 Diabetes

Effect of Different Exercise Training Intensities on Musculoskeletal and Neuropathic Pain in Inactive Individuals with Type 2 Diabetes - Preliminary Randomised Controlled Trial

Diabetes Res Clin Pract.

Cox ER, Gajanand T, Burton NW, Coombes JS, Coombes BK

doi: 10.1016/j.diabres.2020.108168.

COMMENTED

Type 2 Diabetes

Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial

Lancet Diabetes Endocrinol.

Aroda VR, González-Galvez G, Grøn R, Halladin N, Haluzík M, Jermendy G, Kok A, Őrsy P, Sabbah M, Sesti G, Silver R

doi: 10.1016/S2213-

COMMENTED

Type 2 Diabetes

Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial

PLoS Med.

Ruscitti P, Masedu F, Alvaro S, Airò P, Battafarano N, Cantarini L, Cantatore FP, Carlino G, D'Abrosca V, Frassi M, Frediani B, Iacono D, Liakouli V, Maggio R, Mulè R, Pantano I, Prevete I, Sinigaglia L, Valenti M, Viapiana O, Cipriani P, Giacomelli R

doi: 10.1371/

COMMENTED

Diabetes - GeneralType 2 DiabetesGlycemic Control

Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial

Lancet Diabetes Endocrinol.

Pratley RE, Aroda VR, Lingvay I, Lüdemann J, Andreassen C, Navarria A, Viljoen A; SUSTAIN 7 investigators

doi: 10.1016/S2213-8587

Related content

Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials

Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial

Efficacy of the Telemedical Lifestyle intervention Program TeLiPro in Advanced Stages of Type 2 Diabetes: A Randomized Controlled Trial

Use of professional-mode flash glucose monitoring, at 3-month intervals, in adults with type 2 diabetes in general practice (GP-OSMOTIC): a pragmatic, open-label, 12-month, randomised controlled trial

Efficacy and safety of suspend-before-low insulin pump technology in hypoglycaemia-prone adults with type 1 diabetes (SMILE): an open-label randomised controlled trial

Effect of Different Exercise Training Intensities on Musculoskeletal and Neuropathic Pain in Inactive Individuals with Type 2 Diabetes - Preliminary Randomised Controlled Trial

Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial

Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial

Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial